SR One Capital Management, LP

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 12, 2026), SR One Capital Management, LP reported 15 stock positions worth $1.0 billion. Its top holding was Veradermics (MANE) at 28.4% of the portfolio, followed by Zenas Biopharma (ZBIO, 12.3%) and Crispr Therapeutics (CRSP, 10.7%). Compared with Q1 2026, it opened 3 new positions, sold out of 2 and added to 1. The biggest buy was a new position in Avalyn Pharma (AVLN) and the biggest sale an exit from Arcellx (ACLX).

Most Recent 13F
Q2 2026
Location
Redwood City, CA
CIK
0001910264
Portfolio Value
$1.0B (Q2 2026)
SEC Filing
0001193125-26-347065 ↗ filed Aug 12, 2026

Holdings Value

0$500.0M$1.0B$1.5B Q1 2024: $364.1M Q1 2024 Q2 2024: $319.4M Q2 2024 Q3 2024: $498.7M Q3 2024 Q4 2024: $410.1M Q4 2024 Q1 2025: $389.3M Q1 2025 Q2 2025: $461.4M Q2 2025 Q3 2025: $691.4M Q3 2025 Q4 2025: $706.4M Q4 2025 Q1 2026: $915.4M Q1 2026 Q2 2026: $1.0B $1.0B Q2 2026

Holdings 15 stocks · $1.0B
MANE Veradermics Inc. 28.42% 2,401,868 $295.3M No change
ZBIO Zenas Biopharma Inc. 12.31% 5,037,854 $127.9M No change
CRSP Crispr Therapeutics AG 10.70% 2,038,763 $111.2M No change
AVLN Avalyn Pharma Inc. 10.48% 3,308,649 $108.9M New
DSGN Design Therapeutics Inc. 9.09% 6,526,476 $94.4M No change
ODTX Odyssey Therapeutics Inc. 6.83% 3,794,883 $71.0M New
ALMS Alumis Inc. 5.31% 1,959,896 $55.2M No change
ORIC Oric Pharmaceuticals Inc. 4.81% 4,615,384 $50.0M Add +2.2%
MLYS Mineralys Therapeutics Inc. 4.06% 1,563,966 $42.2M No change
SPRY Ars Pharmaceuticals Inc. 3.09% 4,012,903 $32.1M No change
MOBI Mobia Medical Inc. 2.56% 1,986,072 $26.6M New
NKTX Nkarta Inc. 0.91% 3,333,333 $9.4M No change
OCS Oculis Holding AG 0.86% 641,022 $8.9M No change
RARE Ultragenyx Pharmaceutical Inc. 0.44% 137,753 $4.6M No change
ENGN Engene Holdings Inc. 0.12% 747,750 $1.3M No change

Portfolio Sells Q1 2026 → Q2 2026
ACLX Arcellx Inc. Sold out 0.00% −29.43
ORKA Oruka Therapeutics Inc. Sold out 0.00% −2.31

Portfolio Buys Q1 2026 → Q2 2026
AVLN Avalyn Pharma Inc. New 10.48% +10.48
ODTX Odyssey Therapeutics Inc. New 6.83% +6.83
MOBI Mobia Medical Inc. New 2.56% +2.56
ORIC Oric Pharmaceuticals Inc. Add +2.2% 4.81% −1.58

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 15$1.0BMANE, ZBIO, CRSP, AVLN, DSGN
Q1 2026 14$915.4MACLX, MANE, ZBIO, CRSP, DSGN
Q4 2025 13$706.4MZBIO, ACLX, CRSP, DSGN, MLYS
Q3 2025 12$691.4MACLX, CRSP, ZBIO, MLYS, ORIC
Q2 2025 13$461.4MACLX, SPRY, CRSP, ZBIO, ORIC
Q1 2025 12$389.3MACLX, SPRY, MLYS, ZBIO, CRSP
Q4 2024 11$410.1MACLX, SPRY, CRSP, DSGN, ZBIO
Q3 2024 11$498.7MACLX, ZBIO, SPRY, CRSP, DSGN
Q2 2024 9$319.4MACLX, CRSP, SPRY, ALMS, MLYS
Q1 2024 6$364.1MACLX, CRSP, SPRY, NKTX, DSGN